Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 7 days
Any time
Past hour
Past 24 hours
Past 30 days
Most recent
Best match
MedPage Today
3d
Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer
In fact, median progression-free survival (PFS) decreased from 20.2 months with rucaparib (Rubraca) monotherapy to 15.0 months with the addition of nivolumab (Opdivo), translating into a hazard ratio ...
Medscape
5d
Nivolumab-Rucaparib Not Superior to Rucaparib as Maintenance Tx for Ovarian Cancer
The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Secret Service admits failure
Kentucky judge fatally shot
Boy kills bear, saves father
Secret Service probing post
Body found in SUV
$230 million crypto theft
Russia threatens retaliation
Feds subpoena Schaeffer
Hold campaign event in MI
Hiker injured in bear attack
WI high court to decide
Pandas leaving for China
1st rabies outbreak in seals
Recalling 449K+ vehicles
Sues pharmacy middlemen
Whooping cough cases spike
Hand count approved in GA
House repeals emission rules
FDA approves flu vaccine
144K+ Mavericks recalled
Jurors begin deliberations
SC 1st execution in 13 years
Bill to boost security OK'd
Stein's ballot bid rejected
Top Hezbollah leader killed?
MS sheriff's office probe
Baby powder recalled
Raises settlement offer
Drug price challenge revived
In-person voting begins
PGA welcomes LIV players
Disney to stop using Slack
Feedback